This company is no longer active
CHR Stock Overview
Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Chr. Hansen Holding A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 549.60 |
| 52 Week High | DKK 570.20 |
| 52 Week Low | DKK 417.70 |
| Beta | 0.33 |
| 11 Month Change | -2.45% |
| 3 Month Change | 7.47% |
| 1 Year Change | 7.09% |
| 33 Year Change | -4.02% |
| 5 Year Change | -14.18% |
| Change since IPO | 478.53% |
Recent News & Updates
Recent updates
Be Wary Of Chr. Hansen Holding (CPH:CHR) And Its Returns On Capital
Dec 31
Is Chr. Hansen Holding (CPH:CHR) Using Too Much Debt?
Dec 13Chr. Hansen Holding (CPH:CHR) Will Be Hoping To Turn Its Returns On Capital Around
Jun 26These 4 Measures Indicate That Chr. Hansen Holding (CPH:CHR) Is Using Debt Reasonably Well
May 21Chr. Hansen Holding (CPH:CHR) Could Be Struggling To Allocate Capital
Mar 28Chr. Hansen Holding's (CPH:CHR) Shareholders Will Receive A Bigger Dividend Than Last Year
Nov 14Chr. Hansen Holding (CPH:CHR) Is Paying Out A Larger Dividend Than Last Year
Oct 29Chr. Hansen Holding (CPH:CHR) Is Increasing Its Dividend To €7.04
Oct 15Here's What's Concerning About Chr. Hansen Holding's (CPH:CHR) Returns On Capital
Sep 13These 4 Measures Indicate That Chr. Hansen Holding (CPH:CHR) Is Using Debt Reasonably Well
Aug 29A Look At The Intrinsic Value Of Chr. Hansen Holding A/S (CPH:CHR)
Aug 13Capital Allocation Trends At Chr. Hansen Holding (CPH:CHR) Aren't Ideal
Jun 12Chr. Hansen Holding (CPH:CHR) Seems To Use Debt Quite Sensibly
May 24A Look At The Fair Value Of Chr. Hansen Holding A/S (CPH:CHR)
May 09There Are Reasons To Feel Uneasy About Chr. Hansen Holding's (CPH:CHR) Returns On Capital
Mar 06Does Chr. Hansen Holding (CPH:CHR) Have A Healthy Balance Sheet?
Feb 19Shareholder Returns
| CHR | DK Chemicals | DK Market | |
|---|---|---|---|
| 7D | -1.2% | -1.0% | -2.1% |
| 1Y | 7.1% | -1.9% | 6.2% |
Return vs Industry: CHR exceeded the Danish Chemicals industry which returned -4.7% over the past year.
Return vs Market: CHR underperformed the Danish Market which returned 27.3% over the past year.
Price Volatility
| CHR volatility | |
|---|---|
| CHR Average Weekly Movement | 3.0% |
| Chemicals Industry Average Movement | 4.4% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 10.4% |
| 10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: CHR has not had significant price volatility in the past 3 months.
Volatility Over Time: CHR's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1843 | 3,834 | Mauricio Graber | www.chr-hansen.com |
Chr. Hansen Holding A/S, a bioscience company, develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. The company operates through Food Cultures & Enzymes, and Health & Nutrition segments. The Food Cultures & Enzymes segment produces and sells various cultures, enzymes, and probiotic products that determine the taste, flavor, texture, shelf life, nutritional value, and health benefits of various consumer products in the food industry, primarily in the dairy industry.
Chr. Hansen Holding A/S Fundamentals Summary
| CHR fundamental statistics | |
|---|---|
| Market cap | DKK 72.33b |
| Earnings (TTM) | DKK 1.69b |
| Revenue (TTM) | DKK 9.94b |
42.8x
P/E Ratio7.3x
P/S RatioIs CHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHR income statement (TTM) | |
|---|---|
| Revenue | €1.33b |
| Cost of Revenue | €611.10m |
| Gross Profit | €723.30m |
| Other Expenses | €496.30m |
| Earnings | €227.00m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
Apr 04, 2024
| Earnings per share (EPS) | 1.72 |
| Gross Margin | 54.20% |
| Net Profit Margin | 17.01% |
| Debt/Equity Ratio | 52.0% |
How did CHR perform over the long term?
See historical performance and comparison